



SEQUENCE LISTING

<110> Novo Nordisk A/S
 Svendsen, Ivan
 Kjaergaard, Kristian
 Zahn, Stefan

<120> Humanized Tissue Factor Antibodies

<130> 6600.200-US

<140> 10/699,362
 <141> 2003-10-31

<150> Danish Application No. 2002 01661
 <151> 2002-11-18

<150> US Application No. 60/427,157
 <151> 2002-11-18

<160> 14

<170> PatentIn version 3.3

<210> 1
 <211> 33
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 1
 gcggccgcca tgtaccgaga ctacggggaa ccg 33

<210> 2
 <211> 29
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 2
 gcggccgctc acaaagccag gagtgtagg 29

<210> 3
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 3
 cagcatgaaa gccttcagtc 20

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 4
 ctctggtgat gcaggctgac 20

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 5
 cgtcaccctt ctccacttga 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 6
 cttggtcttg ctgcatttct 20

<210> 7
 <211> 32
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 7
 actagttttg gctgaggaga cggtgaccgt gg 32

<210> 8
 <211> 32
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic

<400> 8
 actagttttg gctgaggaga ctgtgagagt gg 32

<210> 9
 <211> 32
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 9
 actagttttg gctgcagaga cagtgaccag ag 32

<210> 10
 <211> 32
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 10
 actagttttg gctgaggaga cggtgactga gg 32

<210> 11
 <211> 32
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 11
 tcatcaacac tcattcctgt tgaagctctt ga 32

<210> 12
 <211> 23
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 12
 gtgccagggg gaagaccgat ggg 23

<210> 13
 <211> 32
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 13
 gcaggcacac aacagaggca gttccagatt tc 32

<210> 14
 <211> 263
 <212> PRT
 <213> Homo sapiens

<400> 14

Ser Gly Thr Thr Asn Thr Val Ala Ala Tyr Asn Leu Thr Trp Lys Ser
 1 5 10 15

Thr Asn Phe Lys Thr Ile Leu Glu Trp Glu Pro Lys Pro Val Asn Gln
 20 25 30

Val Tyr Thr Val Gln Ile Ser Thr Lys Ser Gly Asp Trp Lys Ser Lys
 35 40 45

Cys Phe Tyr Thr Thr Asp Thr Glu Cys Asp Leu Thr Asp Glu Ile Val
 50 55 60

Lys Asp Val Lys Gln Thr Tyr Leu Ala Arg Val Phe Ser Tyr Pro Ala
 65 70 75 80

Gly Asn Val Glu Ser Thr Gly Ser Ala Gly Glu Pro Leu Tyr Glu Asn
 85 90 95

Ser Pro Glu Phe Thr Pro Tyr Leu Glu Thr Asn Leu Gly Gln Pro Thr
 100 105 110

Ile Gln Ser Phe Glu Gln Val Gly Thr Lys Val Asn Val Thr Val Glu
 115 120 125

Asp Glu Arg Thr Leu Val Arg Arg Asn Asn Thr Phe Leu Ser Leu Arg
 130 135 140

Asp Val Phe Gly Lys Asp Leu Ile Tyr Thr Leu Tyr Tyr Trp Lys Ser
 145 150 155 160

Ser Ser Ser Gly Lys Lys Thr Ala Lys Thr Asn Thr Asn Glu Phe Leu
 165 170 175

Ile Asp Val Asp Lys Gly Glu Asn Tyr Cys Phe Ser Val Gln Ala Val
 180 185 190

Ile Pro Ser Arg Thr Val Asn Arg Lys Ser Thr Asp Ser Pro Val Glu
 195 200 205

Cys Met Gly Gln Glu Lys Gly Glu Phe Arg Glu Ile Phe Tyr Ile Ile

210

215

220

Gly Ala Val Val Phe Val Val Ile Ile Leu Val Ile Ile Leu Ala Ile
225 230 235 240

Ser Leu His Lys Cys Arg Lys Ala Gly Val Gly Gln Ser Trp Lys Glu
245 250 255

Asn Ser Pro Leu Asn Val Ser
260